Systemic sclerosis

Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome.

A videoconference-based group intervention aimed at reducing anxiety and other mental health symptoms in people with systemic sclerosis does not show immediate benefits but may have a delayed impact, study findings indicate.

People with rheumatic and musculoskeletal diseases treated with rituximab may have a higher risk for developing severe COVID-19 than those given other treatments, researchers report.

Click through for more information on this US approval

The presence of autoimmune rheumatic diseases is not associated with worse survival outcomes among patients with lung cancer, researchers report.

The autotaxin inhibitor ziritaxestat may improve skin fibrosis in patients with early diffuse cutaneous systemic sclerosis, show data from the phase 2a NOVESA study presented at the ACR Convergence 2020 virtual meeting.

Romilkimab could significantly improve skin fibrosis in people with early diffuse cutaneous systemic sclerosis, results of a phase 2 proof-of-concept study suggest.

Autologous hematopoietic stem cell transplantation leads to early and sustained clinically relevant improvements in health-related quality of life among patients with systemic sclerosis, study findings indicate.

Tocilizumab does not significantly improve skin fibrosis in patients with diffuse cutaneous systemic sclerosis but may preserve lung function among individuals with early interstitial lung disease, say researchers.

Retrospectively collected data suggest that patients with autoimmune rheumatic diseases from the Hubei province in China had a greater susceptibility to COVID-19 infection than their family members living in the same household during the outbreak.

Quantitative computed tomography analysis has the potential to identify patients with systemic sclerosis-associated interstitial lung disease with a high 10-year mortality risk

The prevalence of rheumatic diseases is low among patients admitted to the intensive care unit with severe COVID-19, researchers report.

Adults who develop systemic sclerosis at an older age are at greater risk for rapid disease progression than those with a younger age at onset, research suggests.

The cannabinoid receptor type 2 agonist lenabasum may improve clinical outcomes and underlying disease pathology in patients with diffuse cutaneous systemic sclerosis, show the results of a first-in-human study.